Your browser (Internet Explorer 7 or lower) is out of date. It has known security flaws and may not display all features of this and other websites. Learn how to update your browser.


Navigate / search

CTBR/Chemistry Department Seminar Spring 2012: Multifunctional Polyacrylamide-Based Nanoplatforms in Tumor-Imaging and Phototherapy

Event Start Date: 
Friday, May 11, 2012 - 3:00pm
Event End Date: 
Friday, May 11, 2012 - 4:00pm

Professor Ravindra Pandey
Distinguished Professor and Director Photodynamic Therapy
Center Roswell Park Cancer Institute
Buffalo, New York

Refreshments will be served!

Supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health 8 G12 MD007599-27 (formerly NCRR Grant #G12 RR003037)

Abstract: Most of the photosensitizers (PS) investigated and/or being used to date in photodynamic therapy (PDT) are highly fluorescent. This property has been used to guide surgical interventions and PDT. Unfortunately, most of the photosensitizers exhibit small Stokes shift(s) between the long-wavelength absorption and emission and are therefore not desirable candidates for fluorescence imaging of cancer.1 Conversely, certain highly efficient cyanine dye–based fluorophores (non-porphyrin based compounds) generally do not localize within tumors efficiently, but require an additional moiety or process to provide selectivity, such as attachment of a peptide2 or other moieties that bind to a targeted receptor(s) known for high expression in tumors. Promising clinical-PDT results suggest that certain porphyrin-based photosensitizers preferentially accumulate within a wide range of malignancies compared to their normal tissue surroundings. This characteristic has been used in designing bi- and multifunctional agents in which the PS also helps in delivering the desired imaging agent(s) to tumors.1 For quite some time, one of the objectives of our laboratory has been to develop agents that can be used concurrently detect tumors ( via PET, MRI and/or fluorescence) and treat them (with PDT). 1 One of our approaches involves the synthesis, characterization and pre-clinical validation (including in vivo toxicity) of novel conjugates of tumor-avid PS linked to unique near infrared (NIR) fluorescent dyes or the long half-life PET agent labeled with 124I. In another approach, imaging and therapeutic monomers are post-loaded onto biocompatible PAA nanoparticles. Preliminary work shows that some of the multifunctional agents developed in our laboratory provide promising in vivo tumor selectivity while maintaining PDT efficacy.2 This “See and Treat” approach enhances the scope of image guided therapy. Thesynthesis and comparative tumor-imaging and therapeutic potential of the monomers and the corresponding multifunctional nanoplatforms will be discussed.


Hunter College, CUNY

Room 1403 HN

Contact person and information for event: 

Denise Charles, CTBR

dc674 (at) hunter (dot) cuny (dot) edu